Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06833125

The Prophylactic Effect of Garlic Tablets to Prevent Nosocomial Infections in Intensive Care Unit Patients.

The goal of this clinical trial is to learn if garlic tablets works to prevent nosocomial infections in hospitalized patients in ICU. The main questions it aims to answer are:

Does garlic tablets administration lower the occurence of nosocomial infections in hospitalized patients in ICU?

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Nosocomial Infection Cross Infection Disease Attributes Iatrogenic Disease Infections Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Alexandria Main University Hospital

Alexandria, Alexandria Governorate, 21563, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients aged from 18 to 65 years old admitted to intensive care units without any type of infection.

Exclusion criteria

  • Patients with signs /symptoms of infection.
  • Patients with human immunodeficiency virus, malignancy and patients with a history of recent immunosuppressants or corticosteroids administration.
  • Patients with bleeding disorders or abnormal coagulation profile
  • Patients who will planned for surgery within 2 weeks.

Treatment and study plan

Garlic powder standardized to allicin

Drug

The intervention is the administration of garlic tablets (Tomex plus 300 mg) two tablets twice daily (which contains 5.4 mg allicin the active ingredient with anibacterial effect) for 6 days just after ICU admission

Primary outcomes

  1. Occurrence of central line-associated bloodstream infections, catheter- associated urinary tract infections, surgical site infections and ventilator- associated pneumonia in the two groups (by cultures results).

    Time frame: one year

Secondary outcomes

  1. Values of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups .

    Time frame: one year

    The Mean of Blood white cell count (number per micro liter) , body temperature ( by the degree Celsius) and C-reactive protein (milligrams per liter ) of the patients in the two groups will be calculated.

  2. Values of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups .

    Time frame: one year

    The Mean of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups will be calculated.

Other outcomes

  1. Antibiotics consumption as total number of vials per each antibiotic in the two groups.

    Time frame: one year

  2. Lenghth of stay of patients in ICU (by average number of days) in the two groups

    Time frame: one year

  3. Mortality rate of patients in the two groups

    Time frame: one year

Sponsors and collaborators

Lead sponsor

Alexandria University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 18, 2025
Registry last updated
Oct 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.